肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2009年
11期
734-736
,共3页
子宫颈肿瘤%药物疗法%联合%放射疗法%高温%诱发
子宮頸腫瘤%藥物療法%聯閤%放射療法%高溫%誘髮
자궁경종류%약물요법%연합%방사요법%고온%유발
Uterine cervical neoplasms%Drug therapy%combination%Radiotherapy%Hyperthermia,induced
目的 评价深部聚焦热疗联合放化疗治疗局部晚期子宫颈癌的近期临床疗效及患者不良反应.方法 收集局部晚期子宫颈癌患者68例,其中热疗与放化疗联合组30例,放化疗对照组38例,化疗采用FP方案,每周2 d,连用3周,放疗采用常规分割,热疗采用深部聚焦热疗机,提升肿瘤局部温度达42.5℃以上并维持至少30 min,每周2次,共7～12次,均于放疗结束后2 h内进行.两组均于放疗剂量达40 Gy后根据妇科检查及超声结果进行判断,可手术者行根治术,仍无手术指征者追加外照射及~(252)Cf源后装治疗至根治量.结果 所有患者均完成了治疗,联合组手术切除率50.0%(15/30),高于对照组的26.3%(10/38)(P<0.05);联合组的局部有效率为90.0%(27/30),对照组为84.2%(32/38)(P>0.05);联合组的不良反应未高于对照组.结论 热疗联合放化疗可以提高局部晚期子宫颈癌患者的手术切除率及局部控制率,不增加放射反应,可提高患者生活质量.
目的 評價深部聚焦熱療聯閤放化療治療跼部晚期子宮頸癌的近期臨床療效及患者不良反應.方法 收集跼部晚期子宮頸癌患者68例,其中熱療與放化療聯閤組30例,放化療對照組38例,化療採用FP方案,每週2 d,連用3週,放療採用常規分割,熱療採用深部聚焦熱療機,提升腫瘤跼部溫度達42.5℃以上併維持至少30 min,每週2次,共7～12次,均于放療結束後2 h內進行.兩組均于放療劑量達40 Gy後根據婦科檢查及超聲結果進行判斷,可手術者行根治術,仍無手術指徵者追加外照射及~(252)Cf源後裝治療至根治量.結果 所有患者均完成瞭治療,聯閤組手術切除率50.0%(15/30),高于對照組的26.3%(10/38)(P<0.05);聯閤組的跼部有效率為90.0%(27/30),對照組為84.2%(32/38)(P>0.05);聯閤組的不良反應未高于對照組.結論 熱療聯閤放化療可以提高跼部晚期子宮頸癌患者的手術切除率及跼部控製率,不增加放射反應,可提高患者生活質量.
목적 평개심부취초열료연합방화료치료국부만기자궁경암적근기림상료효급환자불량반응.방법 수집국부만기자궁경암환자68례,기중열료여방화료연합조30례,방화료대조조38례,화료채용FP방안,매주2 d,련용3주,방료채용상규분할,열료채용심부취초열료궤,제승종류국부온도체42.5℃이상병유지지소30 min,매주2차,공7～12차,균우방료결속후2 h내진행.량조균우방료제량체40 Gy후근거부과검사급초성결과진행판단,가수술자행근치술,잉무수술지정자추가외조사급~(252)Cf원후장치료지근치량.결과 소유환자균완성료치료,연합조수술절제솔50.0%(15/30),고우대조조적26.3%(10/38)(P<0.05);연합조적국부유효솔위90.0%(27/30),대조조위84.2%(32/38)(P>0.05);연합조적불량반응미고우대조조.결론 열료연합방화료가이제고국부만기자궁경암환자적수술절제솔급국부공제솔,불증가방사반응,가제고환자생활질량.
Objective To evaluate the efficacy and toxicity of hyperthermia combined with chemoradiotherapy for local advanced cervical cancer. Methods Sixty-eight patients with local advanced cervical cancer were treated. Each patient was given cisplatin at the dose of 20 mg ivgtt dl -2 and 5 -fluorouracil 0.75 ivgtt dl -2, repeating every week, total 3 weeks. Thirty -eight patients received chemoradiotherapy alone. Thirty patients received hyperthermia with deeply focus technology, the temperature was increased and maintained 42.5 ℃ for 30 min at least, within 2 hours following irridiation. Hyperthermia was given twice per week with 7 or 12 sessions, as the same chemoradiation methods as the reference group.After 40 Gy therapy to estimate by cervical examination and ultrasonography, the patients with down stage were for operation, and the others continued to irridiation and additional brachytherapy with californium 252until radical dose. Results All patients were tolerated, fifteen patients of hyperthermia combined group were operated and ten patients of the reference group were operated, the difference was significance (50.0 % vs.26.3 %, P <0.05). The response rate of the combined group was 90.0 %, and the reference group was 84.2 %.The incidence of radiotherapy toxicity of the combined group was not higher than the reference group.Conclusion Hyperthermia combined with chemoradiotherapy can elevate the resection rate and the local control rate, not increase the radiotherapy toxicity and increase quality of life for cervical cancer patients.
